Study of CS-3150 in Patients With Primary Aldosteronism

A Study of CS-3150 to Evaluate Efficacy and Safety in Patients With Primary Aldosteronism

To examine antihypertensive effect and safety of CS-3150 in patients with primary aldosteronism.

Inclusion Criteria:

• Male and female subjects aged 20 years or older at informed consent

• Patients diagnosed primary aldosteronism by screening test of plasma aldosterone concentration (PAC) and aldosterone to renin ratio (ARR), and confirmatory testing

• Patients satisfying following blood pressure;

  • sitting systolic blood pressure (SBP) ≥ 140 mmHg and <180 mmHg
  • sitting diastolic blood pressure (DBP) ≥ 90 mmHg and <110 mmHg

Exclusion Criteria:

• Secondary hypertension except primary aldosteronism or hypertensive emergency
• Patients diagnosed diabetic nephropathy
• Patients with type 1 diabetes
• Estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73m2
• Serum potassium level < 3.0 or ≥ 5.1 milliequivalent (mEq)/L